COVID-19 olfactory dysfunction, evaluation of onset, and persistence.

IF 1.4 Q3 Pharmacology, Toxicology and Pharmaceutics Journal of Advanced Pharmaceutical Technology & Research Pub Date : 2023-04-01 Epub Date: 2023-04-13 DOI:10.4103/japtr.japtr_48_23
Abdulhusein Mizhir Almaamuri, Mohammed M Mohammed
{"title":"COVID-19 olfactory dysfunction, evaluation of onset, and persistence.","authors":"Abdulhusein Mizhir Almaamuri,&nbsp;Mohammed M Mohammed","doi":"10.4103/japtr.japtr_48_23","DOIUrl":null,"url":null,"abstract":"<p><p>Olfactory dysfunction (OD) is a common feature of COVID-19. The goal of the study was to define the modes of onset of OD in the clinical course of the disease and to follow the cases for 12-18 months in order to estimate the differences in the recovery time from OD over the course of the disease. We managed to follow a total of 325 patients (females: 198, males: 127) in the Babylon governorate in Iraq. All were COVID-19 patients who should have OD during the course of the disease. COVID-19 infection was established in all patients by swab test, i.e. polymerase chain reaction (PCR) and/or chest computed tomography findings of pneumonia compatible with COVID-19. Detailed medical records were obtained directly from the patients or their relatives. The patients were then followed up by telephone and questioned with structured questionnaires concentrating upon general clinical features and the sense of olfaction. Information about the presence of olfactory disorders, their occurrence, and development was recorded. Based on the onset of OD, the patients were categorized into three groups. Olfactory functions were assessed primarily by face-to-face interview and then (if necessary) by a telephone questionnaire assessing self-reported olfactory function and olfactory-related quality of life, which measures the subjective olfactory capability (SOC). In the first 2 weeks, 148 (45.5%) patients reported complete recovery from OD, of which 90 (73.2%) patients joined at the end of the 1<sup>st</sup> month. OD persistence was observed in 11 (3.3%) patients toward the end of the 1<sup>st</sup> year, in 5 (1.5%) patients at the end of the 15<sup>th</sup> month, and only in two (0.6%) patients at the end of the 18<sup>th</sup> month. We found no significant correlation between the type of onset of OD and the duration and persistence of OD. Most sufferers of COVID-associated OD recover their sense of smell within the 1<sup>st</sup> month.</p>","PeriodicalId":14877,"journal":{"name":"Journal of Advanced Pharmaceutical Technology & Research","volume":"14 2","pages":"137-141"},"PeriodicalIF":1.4000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/99/05/JAPTR-14-137.PMC10226702.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Advanced Pharmaceutical Technology & Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/japtr.japtr_48_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/4/13 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Olfactory dysfunction (OD) is a common feature of COVID-19. The goal of the study was to define the modes of onset of OD in the clinical course of the disease and to follow the cases for 12-18 months in order to estimate the differences in the recovery time from OD over the course of the disease. We managed to follow a total of 325 patients (females: 198, males: 127) in the Babylon governorate in Iraq. All were COVID-19 patients who should have OD during the course of the disease. COVID-19 infection was established in all patients by swab test, i.e. polymerase chain reaction (PCR) and/or chest computed tomography findings of pneumonia compatible with COVID-19. Detailed medical records were obtained directly from the patients or their relatives. The patients were then followed up by telephone and questioned with structured questionnaires concentrating upon general clinical features and the sense of olfaction. Information about the presence of olfactory disorders, their occurrence, and development was recorded. Based on the onset of OD, the patients were categorized into three groups. Olfactory functions were assessed primarily by face-to-face interview and then (if necessary) by a telephone questionnaire assessing self-reported olfactory function and olfactory-related quality of life, which measures the subjective olfactory capability (SOC). In the first 2 weeks, 148 (45.5%) patients reported complete recovery from OD, of which 90 (73.2%) patients joined at the end of the 1st month. OD persistence was observed in 11 (3.3%) patients toward the end of the 1st year, in 5 (1.5%) patients at the end of the 15th month, and only in two (0.6%) patients at the end of the 18th month. We found no significant correlation between the type of onset of OD and the duration and persistence of OD. Most sufferers of COVID-associated OD recover their sense of smell within the 1st month.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
新冠肺炎嗅觉功能障碍、发病评估和持续性。
嗅觉功能障碍(OD)是新冠肺炎的常见特征。该研究的目的是确定疾病临床过程中OD的发病模式,并对病例进行12-18个月的随访,以估计疾病过程中OD恢复时间的差异。我们设法跟踪了伊拉克巴比伦省共325名患者(女性:198人,男性:127人)。所有患者都是新冠肺炎患者,在疾病过程中应该有OD。通过拭子检测,即聚合酶链式反应(PCR)和/或与新冠肺炎兼容的肺炎的胸部计算机断层扫描结果,在所有患者中确定了COVID-19]感染。详细的医疗记录是直接从患者或其亲属那里获得的。然后通过电话对患者进行随访,并对其进行结构化问卷调查,重点关注一般临床特征和嗅觉。记录嗅觉障碍的存在、发生和发展的信息。根据OD的发病情况,将患者分为三组。嗅觉功能主要通过面对面访谈进行评估,然后(如有必要)通过电话问卷进行评估,评估自我报告的嗅觉功能和嗅觉相关的生活质量,测量主观嗅觉能力(SOC)。在前两周,148名(45.5%)患者报告OD完全康复,其中90名(73.2%)患者在第一个月底加入。在第1年末观察到11名患者(3.3%)OD持续存在,在第15个月底观察到5名患者(1.5%)OD持续,在第18个月底仅观察到2名患者(0.6%)OD持续。我们发现OD的发作类型与OD的持续时间和持续性之间没有显著相关性。大多数新冠肺炎相关OD患者在第一个月内恢复嗅觉。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.00
自引率
7.10%
发文量
44
审稿时长
20 weeks
期刊介绍: Journal of Advanced Pharmaceutical Technology & Research (JAPTR) is an Official Publication of Society of Pharmaceutical Education & Research™. It is an international journal published Quarterly. Journal of Advanced Pharmaceutical Technology & Research (JAPTR) is available in online and print version. It is a peer reviewed journal aiming to communicate high quality original research work, reviews, short communications, case report, Ethics Forum, Education Forum and Letter to editor that contribute significantly to further the scientific knowledge related to the field of Pharmacy i.e. Pharmaceutics, Pharmacology, Pharmacognosy, Pharmaceutical Chemistry. Articles with timely interest and newer research concepts will be given more preference.
期刊最新文献
Potential antioxidant and antiradical agents from Allium ascalonicum: Superoxide dismutase and density functional theory in silico studies. Potential target and mechanism exploration from α-mangostin against triple-negative breast cancer: An in silico study. Role of Moringa oleifera irrigation solution on the cell metabolism change of Streptococcus mutans. Bioadhesive polymer in antifungal drug delivery for therapeutic treatment of candidiasis. Botanical and pharmacognostic investigation of Strobilanthes kalimantanensis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1